◎
Glycan-first recognitionMulti-lectin capture strategy
⌁
DEP microfluidicsIntrinsic polarizability separation
◉
Single-vesicle analysisFACS & molecular readout
✧
Translational researchFrom feasibility to validation
Our business areas

Two distinct business areas.

Nanopeutics is developing two technology businesses: liquid biopsy for cancer-associated extracellular vesicles and liposome technology focused on Oxysome in hydrogel.

Business Area 01

Liquid Biopsy

A glycan-targeted extracellular vesicle analysis platform combining lectin-functionalized Janus nanoparticles, microfluidic enrichment, fluorescence detection, and molecular profiling.

Cancer applications

  • Glioblastoma (GBM) — Research focused on recurrence monitoring and characterization of GBM-associated extracellular vesicles.
  • Pancreatic cancer — Biomarker discovery and exploratory extracellular-vesicle analysis.
Explore liquid biopsy →
Business Area 02

Liposome Technology

Two liposome-based development programs: Oxysome in hydrogel and doxorubicin-loaded liposome gel.

Technology programs

  • Oxysome in Hydrogel — Oxygen-containing liposome technology for potential topical cosmetic applications.
  • Doxorubicin Liposome Gel — Biopolymer-connected liposome gel platform investigated for sustained local delivery of encapsulated doxorubicin.
Explore doxorubicin liposome gel →
Platform overview

Recognize glycans. Enrich vesicles. Read molecular cargo.

Rather than relying exclusively on individual protein markers, Nanopeutics is developing a multi-lectin approach to recognize aberrant glycosylation patterns associated with cancer-derived extracellular vesicles.

How the platform works →
01 · CAPTURE

Lectin-JNP

Glycan-aware binding

02 · ENRICH

DEP

Microfluidic isolation

03 · DETECT

FACS

Single-vesicle signals

04 · PROFILE

RT-qPCR

Molecular readout

GBM development aims

From glycan capture to molecular readout.

Three connected development aims illustrate the proposed workflow, from selective nanoparticle capture through microfluidic enrichment to molecular analysis.

GBM-associated extracellular vesicle capture using lectin-functionalized Janus nanoparticles
AIM 1 · CAPTURE

Optimize lectin-functionalized nanoparticle capture

Develop selective capture of GBM-associated extracellular vesicles using glycan-targeted Janus nanoparticles.

Dielectrophoresis microfluidic enrichment module
AIM 2 · ENRICH

Develop a nondestructive microfluidic EP module

Enrich nanoparticle–EV complexes while separating free nanoparticles and unbound biological background.

Fluorescence detection, EV marker confirmation, vesicular RNA analysis, and GBM molecular readout
AIM 3 · ANALYZE

Integrate molecular readout and sample feasibility

Combine fluorescence detection, EV marker confirmation, vesicular RNA analysis, and preliminary GBM molecular readout.

Research & partnerships

Advancing with academic and clinical collaborators.

Prior feasibility work in pancreatic cancer and ongoing GBM assay development inform our next research milestones. We welcome collaborators in neuro-oncology, pancreatic cancer, extracellular vesicles, microfluidics, and molecular diagnostics.

Start a collaboration ↗

Research-stage platform

Current efforts include GBM-specific lectin-panel adaptation, optimization of the microfluidic enrichment workflow for CSF and blood, and establishment of analytical performance characteristics.

Platform descriptions on this site are for research and development; they do not represent a cleared or approved clinical diagnostic.

Cancer program · 01

Glycan-targeted liquid biopsy for GBM.

Research program focused on glioblastoma recurrence monitoring through enrichment and molecular characterization of disease-associated extracellular vesicles.

Scientific illustration of glycan-targeted Janus nanoparticles binding extracellular vesicles with DEP microfluidic enrichment and a glioblastoma brain model
Clinical research rationale

A monitoring challenge beyond anatomical imaging.

GBM remains difficult to monitor longitudinally. MRI findings may be confounded by treatment effects, while tissue biopsy is invasive and often unsuitable for repeated sampling. Nanopeutics is investigating whether glycan-targeted sEV enrichment can support complementary molecular monitoring research.

Program aims

  • ✓ Reconfigure multi-lectin panel for GBM-associated glycan patterns.
  • ✓ Optimize DEP enrichment for CSF and blood-derived specimens.
  • ✓ Integrate single-vesicle FACS detection and downstream RT-qPCR.
  • ✓ Establish analytical performance: recovery, background, reproducibility, and molecular yield.

Exploratory biomarker strategy

  • → Glycan signatures / hyper-sialylation recognized by lectin cocktail.
  • → sEV-associated molecular cargo; candidate targets such as EGFRvIII only where justified by study design.
  • → Orthogonal confirmation by vesicle markers and molecular assays.
  • → CSF as a prioritized matrix; plasma/blood as complementary research matrices.
Research status: GBM-specific assay adaptation and clinical performance characterization remain development objectives. No diagnostic sensitivity, specificity, or clinical utility is claimed.
Collaborative research

Specimens, disease biology, and assay validation.

Potential collaboration areas include access to appropriately consented/de-identified archived GBM CSF, neuro-oncology expertise, molecular target selection, and independent assay benchmarking.

Clinical specimen research

Archived CSF and matched blood specimens under institutional approvals and material-transfer requirements.

Neuro-oncology

Study design around recurrence, treatment response, and pseudoprogression questions.

Analytical validation

Recovery, specificity, repeatability, carryover, and orthogonal molecular confirmation.

Cancer program · 02

Pancreatic cancer biomarker discovery.

Pancreatic cancer is the platform's preliminary feasibility foundation, with lectin-JNP binding, exosome capture, DEP integration, and exploratory patient-serum molecular analysis described in the company pitch deck.

Scientific illustration of glycan-targeted Janus nanoparticles binding extracellular vesicles with DEP microfluidic enrichment and a glioblastoma brain model
Liposome Technology

Liposome-based delivery platforms

For oxygen delivery and sustained drug release.

Liposome Technology: liposome-based delivery platforms for oxygen delivery and sustained drug release, showing Oxysome in hydrogel and doxorubicin-loaded liposome gel.
Liposome Technology · Oxysome

Oxysome in Hydrogel

Oxysome is Nanopeutics’ oxygen-containing liposome technology, presented in a hydrogel formulation for potential topical cosmetic applications.

Illustration of oxygen-containing liposomes dispersed in a hydrogel

Preliminary Oxysome Characterization

Oxygen-loaded nanovesicles with particle sizes of approximately 124–143 nm, zeta potential of approximately −42 to −39 mV, and dissolved oxygen concentrations of approximately 20–23 mg/L.

Primary Formulation Strategy

Incorporate Oxysome into a cosmetic-compatible aqueous gel.

Liposome Technology · Drug Delivery

Doxorubicin-Loaded Liposome Gel

A biopolymer-connected liposome gel platform for sustained local delivery of encapsulated doxorubicin.

Gel Network Formation

Hydrophobically modified polymer inserts hydrophobic side chains into liposomal bilayers, connecting liposomes into a network.

Sustained Local Drug Release

Sustained doxorubicin release from liposome gels for more than one week, with an in-vitro cytotoxicity effect.

Preliminary evidence · Research-stage

Feasibility signals supporting continued development.

Company materials describe prior feasibility work in pancreatic cancer cell lines and patient serum. These findings are preliminary and should be interpreted in the context of study design, sample size, and independent validation.

Evidence described in company materials

  • ✓ Lectin-JNP binding affinity assessed on cell membranes.
  • ✓ TEM imaging reported exosomes bound to AAL-JNP.
  • ✓ Flow cytometry and fluorescence microscopy evaluated SNA/AAL lectin-JNP signals.
  • ✓ PANC-1 cell-line proof-of-concept described.

Patient-serum and molecular work

  • → DEP-based exosome capture workflow and Exo-chip concept.
  • → Patient serum/control sample comparison described.
  • → qRT-PCR reported for GPC-1 and MSLN in isolated vesicles.
  • → Company deck reports comparison with CA19-9; independent, prospective validation remains necessary.
Important: Preliminary results are not a validated diagnostic claim. Any comparative performance statement requires review of underlying data, cohort size, statistical methods, and publication status.
Program development

From pancreatic feasibility to broader biomarker research.

Pancreatic cancer work supports optimization of the platform's glycan recognition and EV workflow. Future research can examine marker panels, sample matrices, reproducibility, and independent cohort validation.

Glycan profiling

Lectin-array and glycan recognition studies to explore disease-associated surface patterns.

EV characterization

Capture, enrichment, fluorescence, vesicle-marker confirmation, and molecular cargo analysis.

Validation partnerships

Collaborations with pancreatic oncology, pathology, and translational biomarker groups.

Technology deep dive

A glycan-first approach to EV enrichment.

An integrated workflow connecting lectin-functionalized Janus nanoparticles, dielectrophoretic microfluidics, single-vesicle FACS detection, and RT-qPCR molecular profiling.

Scientific illustration of glycan-targeted Janus nanoparticles binding extracellular vesicles with DEP microfluidic enrichment and a glioblastoma brain model
Integrated workflow

Four connected technology modules.

The platform is designed to address biological heterogeneity by recognizing glycan-associated patterns rather than depending solely on one protein marker.

01 · GLYCAN TARGETING

Lectin-functionalized Janus nanoparticles

A multi-lectin cocktail is designed to engage aberrant glycosylation patterns, including hyper-sialylation-associated signatures.

02 · ISOLATION

DEP microfluidics

Dielectrophoretic separation leverages intrinsic polarizability differences to enrich nanoparticle–EV complexes and preserve vesicle integrity.

03 · DETECTION

FACS-based single-vesicle readout

Fluorescence-activated cell sorting is proposed for single-vesicle signal detection and downstream analysis.

04 · MOLECULAR READOUT

RT-qPCR profiling

Isolated vesicle cargo can be investigated using RT-qPCR and other orthogonal molecular characterization methods.

Platform differentiators (design rationale)

  • ✓ Glycan-first recognition may reduce dependence on variable individual protein markers.
  • ✓ Integrated capture, enrichment, and molecular readout in a coordinated workflow.
  • ✓ Microfluidic development may support repeatability and future scale-up.
  • ✓ Intact vesicle preservation is a design objective for downstream cargo analysis.

Development and validation priorities

  • → Lectin panel optimization by disease and matrix.
  • → Recovery, purity, background, and free nanoparticle carryover.
  • → Device and process reproducibility.
  • → FACS gating, controls, and orthogonal vesicle confirmation.
  • → Molecular assay performance and clinical research validation.
Research & development

Research designed for translation.

Current development priorities

From feasibility to performance characterization.

01

Reagent & assay optimization

Refine lectin panel composition, nanoparticle conjugation, and disease-specific capture conditions.

02

Device & process reproducibility

Establish repeatable DEP microfluidic operation, recovery, background, and carryover controls.

03

Integrated analytical readout

Connect fluorescence/FACS detection, vesicle confirmation, and RT-qPCR or other molecular analysis.

Collaboration ecosystem

Academic, clinical, and technical partners.

Nanopeutics is currently developing our platform in collaboration with Johns Hopkins and University of Maryland Medical School.

Partner with us

  • ✓ Specimen-based assay feasibility and validation
  • ✓ GBM and pancreatic cancer biomarker research
  • ✓ Microfluidic, FACS, and molecular assay development
  • ✓ Translational study design and commercialization
Research collaboration form ↗
Business development

Two business areas. One biotechnology company.

Nanopeutics is advancing two business areas: liquid biopsy for glioblastoma and pancreatic cancer, and liposome technology focused on Oxysome in hydrogel.

Investment thesis

Platform strategy across two business areas

Technology

Liquid biopsy technology for cancer-associated extracellular vesicles, and Oxysome liposome technology in hydrogel.

Initial focus

GBM and pancreatic cancer under the liquid biopsy business, and Oxysome in hydrogel under the liposome business.

Potential pathways

Research services and future licensing for liquid biopsy; formulation partnerships and potential cosmetic product development for the liposome business.

Business model

Two business areas with distinct development pathways.

Nanopeutics is pursuing separate commercialization pathways for liquid biopsy research and oxygen-loaded liposome technology.

Liquid Biopsy

Sponsored biomarker studies, research sample-processing services, research-use-only workflows, and potential future licensing for GBM and pancreatic cancer applications.

Liposome Business

Oxysome in hydrogel for potential topical cosmetic applications, with possible formulation partnerships and technology licensing.

These are development and commercialization pathways under evaluation, not statements of validated product performance, regulatory clearance, or guaranteed revenue.

Leadership & advisors

Scientific vision. Execution.

Nanopeutics brings together expertise across nanotechnology, cancer research, engineering, finance, and regulatory strategy.

Leadership

Company leadership

Profiles below are based on company pitch materials and should be approved by each individual before publication.

JC

Jonghoon Choi, Ph.D.

Founder & Chief Executive Officer

Professor of Convergence Engineering at Chung-Ang University; doctoral training at the University of Maryland and postdoctoral experience at Johns Hopkins Medicine.

JL

Jaeho Lee, Ph.D.

Chief Technology Officer

Biomaterials, radiochemistry, and translational R&D experience including NIH and biotech research leadership.

DC

David Choi

Chief Financial Officer

Senior leadership experience in financial institutions, including Citibank.

Scientific publications & intellectual property

Evidence, methods, and innovation.

A public resource for peer-reviewed publications, patent records, posters, and technical materials associated with Nanopeutics.

Research presentations

Scientific posters, conference abstracts, and technical summaries may be made available subject to permission.

Request research materials ↗
Newsroom

Company updates & research milestones.

Official announcements, research progress, partnerships, and company news.

2026 · Funding

NIH/NCI SBIR Phase I application submitted

Company materials indicate a non-dilutive funding application submitted in 2026. Award status should be updated only when officially confirmed.

Research · Platform

Pancreatic feasibility informs GBM development

Preliminary pancreatic cancer feasibility work supports continued optimization of glycan-targeted EV enrichment workflows.

Research collaboration & contact

Let's advance discovery together.

We welcome inquiries from academic researchers, clinicians, biotech companies, investors, and strategic partners.

Contact Nanopeutics

Start a conversation.

Tell us about your research interests, technical questions, or partnership opportunity. The form prepares an email in your default email application.

Phone
(445) 207-3474

Email
info@nanopeutics.org

Areas of interest · Oxysome · Oxygen-loaded liposomes · Cosmetic formulation
GBM · Pancreatic cancer · EV research · Microfluidics · FACS · Molecular profiling

Collaboration inquiry

No form data is stored or sent by this static website. Your email application opens with the message populated.

Research & medical disclaimer

Nanopeutics technologies described on this website are in research and development. Content is informational and does not constitute medical advice or a claim that a test is validated, cleared, or approved for clinical diagnosis. No clinical use should be inferred.

Forward-looking statements

Statements concerning development plans, potential applications, milestones, market opportunities, financing, and commercialization are forward-looking and subject to risks and uncertainties. Actual outcomes may differ materially; no timeline or result is guaranteed.

Privacy notice · Website draft

This static site does not intentionally collect form submissions on a server. Contact forms open the visitor's email application. Hosting providers may process technical logs. A final policy should disclose hosting, analytics/cookies, retention, data rights, and contact details as applicable.

Terms of use

Website content is provided for general information. Trademarks, images, and technical content may be owned by Nanopeutics or third parties. Do not reproduce proprietary or confidential material without permission. Final terms should be reviewed by legal counsel.